E-DRUG: Independent Drug and Healthcare Newsletter for March 2019
--------------------------------------------------------------------------------------
Newsletter, March 2019
Independent Drug & Healthcare Newsletter from the non-profit journal Prescrire International
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW High-strength insulins: think and act in units of insulin to prevent errors
At home as in hospital (and other healthcare facilities), errors associated with insulin use are numerous, frequent and can have serious consequences. How can dosing errors due to the coexistence of different strengths of insulin on the market be prevented?
Read more
--------------------------------------------------------------------------------
FREE DOWNLOAD In the March issue of Prescrire International: Minor ischaemic stroke and antiplatelet drugs
In this month's free sample text, the results of a trial confirming that after a minor stroke or transient ischaemic attack there is very little advantage from adding clopidogrel to aspirin, which remains the first-choice antithrombotic.
Read more
--------------------------------------------------------------------------------
SUBSCRIBE NOW Subscribe today for full access to top-quality content from Prescrire International
Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries).
Subscribe now
--------------------------------------------------------------------------------
Melatonin: significant adverse effects
Melatonin is not a treatment of choice for sleep disorders: its efficacy beyond that of a placebo is uncertain, and it carries a risk of neuropsychological, cutaneous, gastrointestinal and other adverse effects.
Read more
--------------------------------------------------------------------------------
Publicly-funded research: too opaque!
France's top clinical research institutions, like many public organisations or private foundations financing clinical trials around the world, are not up to the mark when it comes to clinical research transparency.
Read more
--------------------------------------------------------------------------------
ADVANCING HEALTHCARE POLICY It is high time to put an end to EMA's opaque and confidential practice of early scientific advice
In their joint response to the EU Ombudsman's consultation on the pre-submission "scientific advice" provided by EMA to pharmaceutical companies, ISDB and Prescrire argue that it is high time to put an end to EMA's opaque and confidential practice of early scientific advice and to take resolute action to promote independence and transparency.
Read more
--------------------------------------------------------------------------------
COMING SOON Enjoy these features, and more, in our upcoming issues
Drugs to avoid: 2019 update * Sofosbuvir + velpatasvir + voxilaprevir in chronic hepatitis C * Fosfomycin trometamol for pregnant women: many unknowns * Acute colonic diverticulitis * Gabapentin and pregabalin: deaths reported...
Subscribe now
Share this with a friend or colleague: Forward this email
Prescrire International <international@prescrire.org>